Sino Biopharmaceutical has been granted a patent for a method using a compound to treat diseases mediated by P2X3 and/or P2X2/3 receptors. The compound, formula (I), can be administered to patients in need, as per the patent claim. GlobalData’s report on Sino Biopharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sino Biopharmaceutical, was a key innovation area identified from patents. Sino Biopharmaceutical's grant share as of February 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11919918B2) discloses a method for treating diseases mediated by the P2X3 and/or P2X2/3 receptor antagonist. The method involves administering a compound with a specific chemical structure or its derivatives to a subject in need. The compound can be in the form of a salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound, or prodrug. The patent outlines various structural variations and compositions of the compound for effective treatment.
Furthermore, the patent specifies the diseases that can be targeted using this method, including urinary tract diseases like bladder hyperreactivity and benign prostatic hypertrophy, pain diseases such as inflammatory pain and migraine, cardiovascular system diseases, respiratory diseases like asthma, and gastrointestinal diseases such as irritable bowel syndrome. The method involves administering a pharmaceutical composition containing the compound along with a pharmaceutically acceptable carrier. The patent also covers the formulation of the pharmaceutical composition in various forms like solid, semi-solid, liquid, or gas preparations to suit different administration routes and patient needs. Overall, the patent provides a detailed method for treating a range of diseases mediated by specific receptors, offering potential therapeutic options for various medical conditions.
To know more about GlobalData’s detailed insights on Sino Biopharmaceutical, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
